Although CSF levels of PCSK9—the primary protein responsible for degrading APOE-binding receptors—have been reported as elevated in patients with AD in one study (43), we observed no differences in CSF PCSK9 concentrations between AD and control groups. The gene discussed is PCSK9; the disease is Alzheimer disease.